Repligen (NASDAQ:RGEN) Given “Outperform” Rating at Royal Bank of Canada

Repligen (NASDAQ:RGEN)‘s stock had its “outperform” rating restated by research analysts at Royal Bank of Canada in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $190.00 price objective on the biotechnology company’s stock. Royal Bank of Canada’s price target points to a potential upside of 13.70% from the stock’s previous close.

A number of other equities research analysts also recently commented on RGEN. Guggenheim began coverage on Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating for the company. JPMorgan Chase & Co. cut their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and cut their price target for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.00.

Repligen Price Performance

Repligen stock traded up $6.51 during midday trading on Wednesday, reaching $167.10. The company’s stock had a trading volume of 343,671 shares, compared to its average volume of 626,352. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The stock’s 50 day simple moving average is $134.67 and its 200 day simple moving average is $166.12. The firm has a market capitalization of $9.34 billion, a PE ratio of 668.43, a P/E/G ratio of 4.62 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same quarter last year, the company earned $0.53 earnings per share. Repligen’s quarterly revenue was down 3.2% compared to the same quarter last year. On average, equities research analysts forecast that Repligen will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Martin D. Madaus purchased 1,615 shares of the stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the acquisition, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently modified their holdings of the company. YHB Investment Advisors Inc. acquired a new position in shares of Repligen in the 1st quarter valued at about $26,000. Lazard Asset Management LLC lifted its stake in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Repligen in the 2nd quarter valued at about $33,000. Finally, Principal Securities Inc. acquired a new position in shares of Repligen in the 4th quarter valued at about $48,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.